Immunome
Immunome Inc is a clinical-stage biopharmaceutical enterprise headquartered in Bothell, Washington. The company specializes in the discovery and development of novel targeted therapeutic antibodies designed to treat complex oncological and infectious diseases. Its proprietary research platform leverages human memory B-cell analysis to identify and develop potent antibody candidates. Principal revenue is currently earned through research collaborations, pharmaceutical development partnerships, and capital financing arrangements as clinical assets progress through trials. Immunome Inc is publicly listed on the Nasdaq Stock Market.
6 of the funds FundTelligence covers report a position in Immunome.
- Legal name
- IMMUNOME
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 6
- Exposure themes
- Cancer, Treatment, Women's Health
Funds holding Immunome
- DNB Fund Women's Health — DNB · 0.76 % (full portfolio disclosed, August 2026)
- BNP Health Care Innovators — BNP Paribas · 0.62 % (full portfolio disclosed, June 2026)
- JPM US Small Cap Growth Fund — JPM · 0.62 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 0.43 % (full portfolio disclosed, June 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.24 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.2 % (full portfolio disclosed, October 2026)